Alkermes may not be highly rated in the giant Medical-Biomedical/Biotech industry group, but on Monday it stood out by hitting a new all-time high. The stock rose 1.03 to 80.14 in light trade. The rise boosted the midcap stock’s year-to-date gain to more than 36%. Alkermes (ALKS) specializes in difficult diseases of the brain. On Oct. 5, the firm got FDA approval to sell its Aristada drug to treat schizophrenia. In a Bloomberg interview Nov.